The Impact of Antipsychotic Dose Reduction on Clinical Outcomes and Health Care Resource Use Among Medicare Patients with Schizophrenia.

ABSTRACT:

Background

Antipsychotic medications are used to treat schizophrenia and may be associated with adverse effects, including tardive dyskinesia (TD), following prolonged use or upon changes in dosing regimen.

Objective

This retrospective analysis evaluated the burden of antipsychotic dose reduction in Medicare patients with schizophrenia.

Methods

This matched cohort study used Medicare claims data (2006-2017) analyzed for patients with schizophrenia and two or more claims for antipsychotics, with one or more antipsychotic monotherapy period ≥ 90 days. Cohorts were defined for patients with antipsychotic dose reductions ≥ 10% and stable doses. A separate analysis was conducted using patients with dose reductions ≥ 30%. Outcomes included all-cause emergency room (ER) visi

SUBMITTER: Zichlin ML 

PROVIDER: S-EPMC8481169 | biostudies-literature | 2021 Oct

REPOSITORIES: biostudies-literature